| About the author: |
M. V. Bielinskyi, S. V. Fedorov, S. B. Herashchenko, A. S. Herashchenko, I. V. Kozlova, T. Yu. Havrysh |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
Empagliflozin has recently been suggested as a potential cardioprotective agent for breast cancer patients undergoing chemotherapy, a treatment known for its cardiotoxic effects. This study evaluated the effects of empagliflozin on diastolic function and endothelial health in breast cancer patients without prior cardiovascular disease. Sixty-six female patients were divided into two groups: one receiving empagliflozin during chemotherapy, and a control group. The study found that patients treated with empagliflozin exhibited significantly better preservation of diastolic function, as evidenced by smaller declines in the E/A ratio, E/e’ ratio, and left ventricular ejection fraction. Additionally, endothelial function, measured by flow-mediated dilation, was less impaired in the empagliflozin group. These results suggest that empagliflozin may effectively mitigate the cardiotoxic and endothelial adverse effects of chemotherapy, offering a novel approach to protecting cardiovascular health in breast cancer patients. |
| Tags |
breast cancer,cardiotoxicity,chemotherapy,cardioprotection,endothelial dysfunction,empagliflozin,side effects of chemotherapeutic drugs |
| Bibliography |
- Anastasiou M, Oikonomou E, Zagouri F, Siasos G, Antonopoulos AS, Psaltopoulou T, et al. Flow-Mediated Dilation of Brachial Artery as a Screening Tool for Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol. 2017 Dec;70(24):3072. doi: 10.1016/j.jacc.2017.09.1140.
- Bosman M, Favere K, Neutel CHG, Jacobs G, De Meyer GRY, Martinet W, et al. Doxorubicin induces arterial stiffness: A comprehensive in vivo and ex vivo evaluation of vascular toxicity in mice. Toxicol Lett. 2021 Aug; 346:23–33. doi: 10.1016/j.toxlet.2021.04.015.
- Ceriello A, Ofstad AP, Zwiener I, Kaspers S, George J, Nicolucci A. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol [Internet]. 2020;19(1). doi: 10.1186/s12933-020-01147-9 Available from: http://dx.doi.org/10.1186/s12933-020-01147-9.
- Clayton ZS, Brunt VE, Hutton DA, VanDongen NS, D’Alessandro A, Reisz JA, et al. Doxorubicin-Induced Oxidative Stress and Endothelial Dysfunction in Conduit Arteries Is Prevented by Mitochondrial-Specific Antioxidant Treatment. JACC CardioOncol. 2020 Sep;2(3):475–88. doi: 10.1016/j.jaccao.2020.06.010.
- Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019 Mar;20(3): e175–86. doi:10.1016/S1470-2045(19)30026-9.
- Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526–34.
- Florido R, Daya NR, Ndumele CE, Koton S, Russell SD, Prizment A, et al. Cardiovascular Disease Risk Among Cancer Survivors. J Am Coll Cardiol. 2022 Jul;80(1):22–32. doi: 10.1016/j.jacc.2022.04.042.
- Ganbaatar B, Fukuda D, Shinohara M, Yagi S, Kusunose K, Yamada H, et al. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol. 2020; 875:173040.
- Maslova GS, Skrypnyk RІ, Skrypnyk IN. The role of l-ornithine-l-aspartate in prophylaxis of cytostatic-induced liver injury in patients with multiple myeloma. World of Medicine and Biology. 2021; 17(78):100. doi: 10.26724/2079-8334-2021-4-78-100-104.
- Pabel S, Wagner S, Bollenberg H, Bengel P, Kovács Á, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018 Dec 17;20(12):1690–700. doi: 10.1002/ejhf.1328.
- Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020 Oct 8;383(15):1413–24. doi: 10.1056/NEJMOA2022190.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan 8;69(1):7–34. doi: 10.3322/caac.21551.
|
| Publication of the article |
«World of Medicine and Biology» №3(89), 2024 year, 023-028 pages, index UDK 618.19-006.699-08:632.934.3 |
| DOI |
10.26724/2079-8334-2024-3-89-23-28 |
